drugset / Trial / NCT02826018

A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection

NCT02826018 ↗

Phase 1 Terminated 24 enrolled Alnylam Pharmaceuticals
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to determine the safety, tolerability and pharmacokinetics of ALN-HBV in healthy adult volunteers and patients with chronic hepatitis B virus (HBV) infection. In addition, the study will assess antiviral efficacy of ALN-HBV in patients with HBV.

Timeline

Start
2016-06-24
Primary completion
2017-10
Completion
2017-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator ALN-HBV Small interfering RNA (siRNA) — Subcutaneous